Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes

Acta Pharmacologica Sinica

Volumn 28, Issue 4, 2007, Pages 534-539

  Gao, Hong Wei ^a   Xie, Chao ^a   Wang, Hai Ning ^a   Lin, Yu Jing ^a   Hong, Tian Pei ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Acarbose; Asymmetric dimethylarginine; Free fatty acids; Nateglinide

Indexed keywords

ACARBOSE; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; NATEGLINIDE; TRIACYLGLYCEROL;

ADULT; ANALYTIC METHOD; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; DRUG WITHDRAWAL; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL;

ACARBOSE; ARGININE; BLOOD GLUCOSE; CROSS-OVER STUDIES; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; MIDDLE AGED; PHENYLALANINE; PROSPECTIVE STUDIES;

EID: 33947646287     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00534.x     Document Type: Article

References (34)

1. Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004; 6: 133-56.
2. Ikenoue T, Akiyoshi M, Fujitani S, Okazaki K, Kondo N, Maki T. Hypoglycemic and insulinotropic effects of a novel oral anti-diabetic agent, (-)-N-(trans-4-isopropylcyclohexane-carbonyl)-D-phenylalanine (A-4166). Br J Pharmacol 1997; 120: 137-45.
3. Mori Y, Kitahara Y, Miura K, Tajima N. Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading. Endocrine 2004; 23: 39-43.
4. Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 2002; 18: 484-90.
5. de Koning EJ, Rabelink TJ. Endothelial function in the postprandial state. Atheroscler Suppl 2002; 3: 11-6.
6. Shimabukuro M, Higa N, Takasu N, Tagawa T, Ueda S. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in type 2 diabetic patients. Diabet Med 2004; 21: 983-6.
7. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-3.
8. Xiong Y, Lei M, Fu S, Fu Y. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes. Life Sci 2005; 77: 149-59.
9. Annuk M, Zilmer M, Fellstrom B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: impact on cardiovascular disease. Kidney Int Suppl 2003; 84: S50-3.
10. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, et al. Endothelial dysfunction induced by hyperhomocysteinemia: role of asymmetric dimethylarginine. Circulation 2003; 108: 933-8.
11. Bode-Boger SM, Boger RH, Kienke S, Junker W, Frolich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219: 598-603.
12. Taskinen MR. Diabetic dyslipidemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-49.
13. Kelley D, Williams K, Price J, McKolanis T, Goodpaster B, Thaete F. Plasma fatty acids, adiposity and variance of skeletal muscle insulin resistance in type 2 diabetes mellitus. J Clin Endocrinol Metab 2001; 86: 5412-9.
14. Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999; 48: 1836-41.
15. Karpe F. Postprandial lipemia - effect of lipid-lowering drugs. Atheroscler Suppl 2002; 3: 41-6.
16. Bruce D, Chisholm D, Storlien L, Kraegen E. Physiological importance of deficiency in early prandial insulin secretion in non-insulin dependent diabetes. Diabetes 1988; 37: 736-44.
17. Dimitriadis G, Boutati E, Lambadiari V, Mitrou P, Maratou E, Brunel P, et al. Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism. Eur J Clin Invest 2004; 34: 490-7.
18. Johanson EH, Jansson PA, Gustafson B, Sandqvist M, Taskinen MR, Smith U, et al. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes. Diabetes Metab Res Rev 2005; 21: 376-81.
19. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997; 40: 454-62.
20. Panarotto D, Remillard P, Bouffard L, Maheux P. Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. Eur J Clin Invest 2002; 32: 84-92.
21. Damsbo P, Marbury TC, Hatorp V, Clauson P, Muller PG. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes. Diabetes Res Clin Pract 1999; 45: 31-9.
22. Masuda H, Goto M, Tamaoki S, Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol 1999; 126: 211-8.
23. Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002; 51: 843-6.
24. Yasuda S, Miyazaki S, Kanda M, Goto Y, Suzuki M, Harano Y, et al. Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur Heart J 2006; 27: 1159-65.
25. Paiva H, Lehtimaki T, Laakso J, Ruokonen I, Rantalaiho V, Wirta O, et al. Plasma concentrations of asymmetric-dimethylarginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003; 52: 303-7.
26. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 2001; 358: 2096-7.
27. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-6.
28. McLaughlin T, Stuhlinger M, Lamendola C, Abbasi F, Bialek J, Reaven GM, et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrin Metab 2006; 91: 1896-900.
29. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153-7.
30. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
31. Wascher TC, Schmoelzer I, Wiegratz A, Stuehlinger M, Mueller-Wieland D, Kotzka J, et al. Reduction of postchal lenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest 2005; 35: 551-7.
32. Hazama Y, Matsuhisa M, Ohtoshi K, Gorogawa S, Kato K, Kawamori D, et al. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. Diabetes Res Clin Pract 2006; 71: 251-5.
33. Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini E. Betacell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. Diabetes Care 2005; 28: 1132-8.
34. Shimabukuro M, Higa N, Takasu N, Tagawa T, Ueda S. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in type 2 diabetic patients. Diabet Med 2004; 21: 983-6.